Regeneron to showcase progress in advancing novel investigational treatment approaches for a broad range of solid tumors and blood cancers at asco

Oral presentation will feature new data for investigational regn7075, an egfrxcd28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with libtayo ® (cemiplimab-rwlc)

REGN Ratings Summary

REGN Quant Ranking